Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Delivers Targets to Dow AgroSciences

NEW YORK, Nov. 29 – Exelixis said Thursday it had delivered four crop protection targets to Dow AgroSciences under a collaboration deal signed one year ago.

Exelixis of South San Francisco used its Mechanism of Action technology to identify the molecular target of biologically active herbicide and fungicide compounds provided by Dow AgroSciences of Indianapolis. 

Exelixis will receive milestone payments as a result of the discovery. 

"We are eager to move these targets forward to the next phase of lead discovery," Dan Kittle, vice president of Ag Chem and Urban Pest R&D at Dow AgroSciences, said in a statement.

"Dow AgroSciences is confident that this collaboration will continue to efficiently identify high quality targets, which will enable us to speed the discovery and development of new fungicides and herbicides of value to agriculture," he said. 

Dow AgroSciences is a wholly owned subsidiary of the Dow Chemical Company.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.